Propranolol concentrations after oral administration in term and preterm neonates

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 26, Issue 8, 2013, Pages 833-840

  Filippi, L ^a   Cavallaro, G ^b   Fiorini, P ^a   Malvagia, S ^a   Della Bona, M L ^a   Giocaliere, E ^a   Bagnoli, P ^c   Dal Monte, M ^c   Mosca, F ^b   Donzelli, G ^a   La Marca, G ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Beta blocker; Newborn; Pharmacokinetics; Propranolol; Retinopathy of prematurity

Indexed keywords

PROPRANOLOL;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRIED BLOOD SPOT TESTING; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; GESTATIONAL AGE; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NEWBORN; PREMATURITY; PRIORITY JOURNAL; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PROPRANOLOL;

EID: 84876303113     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2012.755169     Document Type: Article

References (46)

1. Bruns LA, Canter CE. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure? Paediatr Drugs 2002;4:771-8 (Pubitemid 36005722)
2. Fritz KI, Bhat AM. Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. J Perinatol 1998;18:38-44. (Pubitemid 128454196)
3. Wong KK, Potts JE, Etheridge SP, Sanatani S. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol 2006;27:199-203.
4. Smith C, Thomsett M, Choong C, et al. Congenital thyrotoxicosis in premature infants. Clin Endocrinol (Oxf) 2001;54:371-6. (Pubitemid 32234202)
5. Mahmoud AB, Tantawy AE, Kouatli AA, Baslaim GM. Propranolol: a new indication for an old drug in preventing postoperative junctional ectopic tachycardia after surgical repair of tetralogy of Fallot. Interact Cardiovasc Thorac Surg 2008;7:184-7. (Pubitemid 351497534)
6. Garin EH, Araya CE. Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr 2009;21:600-4.
7. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51. (Pubitemid 351831393)
8. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010;157:340-2.
9. Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as firstline treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg 2011;137:471-8.
10. Missoi TG, Lueder GT, Gilbertson K, Bayliss SJ. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol 2011;129:899-903.
11. Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. A metaanalysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol 2011;75:455-60.
12. Chim H, Armijo BS, Miller E, et al. Propranolol induces regression of hemangioma cells through HIF-1a-mediated inhibition of VEGF-A. Ann Surg 2012;256:146-56.
13. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 2011;52:155-70.
14. Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of b2-adrenergic receptor blockade in a mouse model of oxygeninduced retinopathy. J Neurochem 2011;119:1317-29.
15. Dal Monte M, Martini D, Latina V, et al. Beta-adrenoreceptor (b-AR) agonism influences retinal responses to hypoxia in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2012;53:2181-92.
16. Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: safety and efficacy of propranolol in newborns with retinopathy of prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 2010;10:83.
17. Leahey WJ, Neill JD, Varma MP, Shanks RG. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol 1980;9:33-40. (Pubitemid 10176893)
18. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. Br J Clin Pharmacol 1984;18:37-43. (Pubitemid 14057120)
19. Serlin MJ, Orme ML, MacIver M, et al. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol 1983;15:519-27. (Pubitemid 13124875)
20. Wójcicki J, Jaroszynska M, Droździk M, et al. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm Drug Dispos 2003;24:211-8. (Pubitemid 36939693)
21. Chidsey CA, Morselli P, Bianchetti G, et al. Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation 1975;52:313-8.
22. Wood AJ, Carr K, Vestal RE, et al. Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol 1978;6:345-50. (Pubitemid 8393855)
23. Nies AS, Shand DG. Clinical pharmacology of propranolol. Circulation 1975;52:6-15.
24. la Marca G, Malvagia S, Filippi L, et al. Rapid assay of topiramate in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J Pharm Biomed Anal 2008;48:1392-6.
25. la Marca G, Malvagia S, Filippi L, et al. A new rapid micromethod for the assay of phenobarbital from dried blood spots by LC-tandem mass spectrometry. Epilepsia 2009;50:2658-62.
26. la Marca G, Malvagia S, Filippi L, et al. Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. J Pharm Biomed Anal 2011;54:192-7.
27. la Marca G, Giocaliere E, Villanelli F, et al. Development of an UPLC-MS/MS method for the determination of antibiotic ertapenem on dried blood spots. J Pharm Biomed Anal 2012;61:108-13.
28. Filippi L, la Marca G, Fiorini P, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 2009;50:2355-61.
29. Filippi L, la Marca G, Cavallaro G, et al. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. Epilepsia 2011;52:794-801.
30. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259-66.
31. Przewratil P, Sitkiewicz A, Andrzejewska E. Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Cytokine 2010;49:141-7.
32. Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-64. (Pubitemid 24177146)
33. Iaccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005;97:1182-9.
34. Annabi B, Lachambre MP, Plouffe K, et al. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009;60:438-45.
35. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298-304. (Pubitemid 35204978)
36. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133-40. (Pubitemid 46440629)
37. Praveen V, Vidavalur R, Rosenkrantz TS, Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics 2009;123:e484-9.
38. Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008;153:712-5.
39. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003;55:667-86. (Pubitemid 36428679)
40. Koren G. Therapeutic drug monitoring principles in the neonate. Natl Acad Clin Biochem Clin Chem 1997;43:222-7. (Pubitemid 27024420)
41. Wilson JT, Atwood GF, Shand DG. Disposition of propoxyphene and propranolol in children. Clin Pharmacol Ther 1976;19:264-70.
42. Ponce FE, Williams LC, Webb HM, et al. Propranolol palliation of tetralogy of Fallot: experience with long-term drug treatment in pediatric patients. Pediatrics 1973;52:100-8.
43. Gibaldi M, Boyes RN, Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci 1971;60:1338-40.
44. Shand DG, Sell CG, Oates JA. Hypertrophic obstructive cardiomyopathy in an infant-propranolol therapy for three years. N Engl J Med 1971;285:843-4.
45. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989;46:257-63. (Pubitemid 19254757)
46. Sowinski KM, Lima JJ, Burlew BS, et al. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 1996;42:339-46. (Pubitemid 26284423)